CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.

@article{Wei2019CYP2D610PS,
  title={CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.},
  author={Xiaoxia Wei and Jiaqin Cai and J. Zhuang and Bin Zheng and Yuxia Sui and Guifeng Zhang and Y. Lin and H. Sun},
  journal={Pharmacogenomics},
  year={2019}
}
  • Xiaoxia Wei, Jiaqin Cai, +5 authors H. Sun
  • Published 2019
  • Medicine
  • Pharmacogenomics
  • Aim: To assess the cost-effectiveness of CYP2D6*10 genetic testing for the management of Chinese women with hormone receptor-positive (HR+) breast cancer treated with selective estrogen receptor modulator. Methods: A Markov model was developed to evaluate a total expected cost and an incremental cost-effectiveness ratio (ICER). Robustness of the model was addressed in one-way analyses and probabilistic sensitivity analysis. Results: The cost of strategies of tamoxifen, toremifene without… CONTINUE READING
    1 Citations
    Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    • 6

    References

    SHOWING 1-10 OF 22 REFERENCES
    Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    • 16
    • PDF